

Network Analysis of Mutations Across Cancer Types

Ben Raphael

Fabio Vandin, Max Leiserson, Hsin-Ta Wu




BROWN


Department of Computer Science
Center for Computational Molecular Biology

Significantly Mutated Genes

Mutation Matrix





Statistical test




Study	Num. Samples	Num. SMG
TCGA Ovarian (2011)	316	10
TCGA Breast (2012)	510	35
TCGA Colorectal (2012)	276	32

Significantly Mutated Genes → Pathways

Statistical test




TCGA Colorectal (*Nature* 2012)




TCGA Ovarian
(*Nature* 2011)

Advantages of Large Datasets


Prior knowledge of groups of genes



Known pathways



Interaction Network





None

Prior knowledge

- Novel pathways or interactions between pathways (*crosstalk*)
- Topology of interactions

Two Algorithms

Prior knowledge of groups of genes



Known pathways

Interaction Network

None

Prior knowledge

Number of Hypotheses

HotNet

Dendrix

subnetworks of
interaction network

Exclusive gene sets

HotNet: Problem Definition



Given:

1. Network $G = (V, E)$

V = genes. E = interactions b/w genes

2. Binary mutation matrix



■ = mutated
□ = not mutated



Find: *Connected subnetworks* mutated in a **significant** number of patients.

Subnetwork Properties

Mutation frequency/score AND network topology




- Moderate frequency/score
- Highly connected


- High frequency/score
- Connected through high-degree node.

Mutated subnetworks: *HotNet**

Mutation Matrix



Human Interaction Network



(1)

Mutation \rightarrow *heat diffusion*


Extract "significantly hot" subnetworks

(2)

Hot





Cold





*F. Vandin, E. Upfal, and B. J. Raphael. *J. Comp. Biol.* (2011). Also *RECOMB* (2010).

Statistical Test

Mutation Matrix



Random Binary Matrix




$X_s = \text{number of subnetworks } \geq s \text{ genes}$

Two-stage multi-hypothesis test: Rigorously bound FDR.


HotNet PanCancer: Goals

Find subnetworks/pathways:


1. Mutated *across* all cancer types.




2. Mutated in a subset of cancer types.




3. Mutated *across* all/many cancer types, but with type-specific mutations.



HotNet PanCancer



Interaction network
> 10K proteins
> 200K interactions




Mutation &
copy number

HotNet




HotNet PanCancer

SNVs (nonsynonymous) and small indels




$\geq 0.8\%$ frequency
or significant in ≥ 1 cancer type

Copy number aberrations




Target gene selection: GISTIC max peaks



Interaction network
> 10K proteins
> 200K interactions

Thousands Patients















Mutation &
copy number




Mutation Data Summary

Total: 765 genes, 1984 samples


	<i>Cancer (sub)type</i>	<i>Num samples</i>
	AML	200
	COADREAD	185
	GBM	261
	Basal-like	87
	HER2	BRCA 61
	LuminalA	
	LuminalB	119
	KIRC	292
	LUSC	86
	OV	311
	UCEC	166



HotNet: iRef Network




iRef 9.0 network
212,746 interaction
14,384 proteins



Mutation &
copy number



HotNet



11 subnetworks with ≥ 3 genes ($P < 0.01$)

iRef Summary


Subnetwork	Coverage
TP53, MDM4, MDM2, STK11, RNF20	48.6% (964 / 1984 samples)
PIK3CA, KRAS, NRAS, IRS2	45.6% (904 / 1984 samples)
EGFR, ERBB2, ERBB3, INSR, KIT, NTRK1, PDGFRB, CBLB	44.3% (878 / 1984 samples)
RBI, CDKN2A, CDK4, CCND1, CEBPA,, DNMT1	40.1% (796 / 1984 samples)
BRIP1, ATR, TP53BP1, BLM, BRCA1, FANCA, FANCM	32.3% (641 / 1984 samples)
PTEN, PIK3R1, PDGFRA, SOS1	32.1% (636 / 1984 samples)
BAP1, ASXL1, ASXL2, ANKHD1-EIF4EBP3, HCFC1, ANKRD17,	30.8% (611 / 1984 samples)
CTNNB1, MYO7A, KDR, CDH1	29.4% (584 / 1984 samples)
Cohesin	28.8% (571 / 1984 samples)
MYC, SETDB1, DNMT3A	28.7% (569 / 1984 samples)
ARID1A, ARID2, BAZ1B	13.2% (261 / 1984 samples)

Mutations Types

■ SNV ■ AMP ■ DEL


TP53, STK11, MDM4, *et al.*

Coverage: 48.2% (957/1984 samples)



Mutations / Gene

778
741
704
667
630
593
556
519
482
445
408
370
333
296
259
222
185
148
111
74
37



Mutations by Cancer

- AML (7.5%)
- Luminal A (25.1%)
- Luminal B (58.8%)
- Basal-like (931.%) ($p = 5.73 \times 10^{-19}$)
- HER2-enriched (82%)
- COADREAD (63.2%) ($p = 0.0001$)
- GBM (48.3%)
- KIRC (5.1%)
- OV (95.2%) ($p = 1.18 \times 10^{-83}$)
- UCEC (40.4%)
- LUSC (76.7%) ($p = 3.88 \times 10^{-7}$)

PIK3CA and RAS interactions

Mutations Types

■ SNV ■ AMP ■ DEL

Coverage: 42.4% (842/1984 samples)




D.J. Burgess.

Nature Reviews Cancer **11**, 389 (June 2011)

Mutations / Gene

- 778
- 741
- 704
- 667
- 630
- 593
- 556
- 519
- 482
- 445
- 408
- 370
- 333
- 296
- 259
- 222
- 185
- 148
- 111
- 74
- 37



Mutations by Cancer


- AML (11.5%)
- Luminal A (56.3%) ($p = 0.0001$)
- Luminal B (51.3%)
- Basal-like (57.5%)
- HER2-enriched (59%)
- COADREAD (61.1%) ($p=7.91 \times 10^{-7}$)
- GBM (16.9%)
- KIRC (11.3%)
- OV (66.9%) ($p = 3.12 \times 10^{-20}$)
- UCEC (63.3%) ($p = 1.68 \times 10^{-7}$)
- LUSC (54.7%)

Mutations Types



DNA Repair


Coverage: 28.8% (572/1984 samples)



Mutations / Gene

- 778
- 741
- 704
- 667
- 630
- 593
- 556
- 519
- 482
- 445
- 408
- 370
- 333
- 296
- 259
- 222
- 185
- 148
- 111
- 74
- 37

HER2-enriched: 0.00078
LuminalB: 0.00084



Mutations by Cancer



- AML (0.5%)
- Luminal A (20%)
- Luminal B (42%)
- Basal-like (54.%) ($p = 4.91 \times 10^{-6}$)
- HER2-enriched (68.9%) ($p = 6.60 \times 10^{-10}$)
- COADREAD (21.1%)
- GBM (16.1%)
- KIRC (15.4%)
- OV (60.5%) ($p = 2.75 \times 10^{-36}$)
- UCEC (22.9%)
- LUSC (43%)

Cohesin Complex

Mutations Types


■ SNV ■ AMP ■ DEL

Coverage: 22% (437/1984 samples)



Mutations / Gene


- 778
- 741
- 704
- 667
- 630
- 593
- 556
- 519
- 482
- 445
- 408
- 370
- 333
- 296
- 259
- 222
- 185
- 148
- 111
- 74
- 37



Mutations by Cancer

- AML (13%)
- Luminal A (14.9%)
- Luminal B (26.1%)
- Basal-like (40.2%) ($p = 0.0008$)
- HER2-enriched (45.9%) ($p = 0.0002$)
- COADREAD (13%)
- GBM (9.6%)
- KIRC (9.9%)
- OV (54%)
- UCEC (11.4%)
- LUSC (23.3%)

Polycomb group proteins



Cancer types

- AML (8)
- BRCA (15)
- COADREAD (12)
- GBM (4)
- KIRC (27)
- OV (6)
- UCEC (34)

Mutation type

- SNV
- CNA


Mutations / Gene

1 2 3 4 5 7 9 12 17 23 32 44 60 82 112 153 210 287 393 538 737

Polycomb Group Proteins

Mutations Types


■ SNV ■ AMP ■ DEL



Coverage: 29% (575/1984 samples)

Mutations / Gene

778
741
704
667
630
593
556
519
482
445
408
370
333
296
259
222
185
148
111
74
37




PR-DUB complex


Mutations by Cancer

- AML (4.5%)
- Luminal A (19.1%)
- Luminal B (29.4%)
- Basal-like (49.4%) ($p = 0.0003$)
- HER2-enriched (41%)
- COADREAD (23.8%)
- GBM (7.7%)
- KIRC (44.5%) ($p = 7.49 \times 10^{-9}$)
- OV (54.7%) ($p = 2.50 \times 10^{-24}$)
- UCEC (20.5%)
- LUSC (27.9%)

HotNet: HPRD Network




HPRD 9.0 network
39,173 interaction
9,617 proteins



Mutation &
copy number



HotNet



20 subnetworks with ≥ 3 genes ($P < 0.01$)

HPRD Summary

Subnetwork	Coverage
PIK3CA and neighbors	64.8% (1286 / 1984 samples)
ARID1A, PBRM1, and neighbors	64.6% (1281 / 1984 samples)
Cohesin and neighbors	47.6% (945 / 1984 samples)
C3, THBS1, CFH, COL3A1, ITGAX, LAMA1	30.7% (609 / 1984 samples)
TG, LPA, ANKS1B, LRP2	28.2% (559 / 1984 samples)
AXIN2, RPI, APC, PTPN13	27.0% (535 / 1984 samples)
BRIPI, BAPI, BRCA1	24.3% (483 / 1984 samples)
PTPRS, CDH1, PTPRK, PPFIA2, PTPRM	24.3% (482 / 1984 samples)
MYC, DNMT3A, DNMT1	22.8% (453 / 1984 samples)
ANK1, LICAM, NCAN, TNC	21.9% (435 / 1984 samples)
CCNE1, NOTCH3, NOTCH4, FBXW7	20.5% (406 / 1984 samples)
SLIT3, ROBO2, ROBO1, SLIT2, SRGAP1	17.9% (355 / 1984 samples)
MCL1, BCL2L1, BCLAF1	16.8% (333 / 1984 samples)
NTRK1, NTRK3, RASGRF1	16.3% (324 / 1984 samples)
MYO7A, NFE2L2, KEAP1	16.1% (319 / 1984 samples)
MLLT4, EPHA7, NRXN3	15.2% (302 / 1984 samples)
COL4A1, COL4A5, COL4A6, FBLN2	11.8% (234 / 1984 samples)
OPRM1, GRM1, GPRASP1	10.8% (215 / 1984 samples)
CDH18, CDH12, CDH10, CDH9	10.6% (211 / 1984 samples)
FLNA, CALCR, GRM8, CASR	10.1% (201 / 1984 samples)

HPRD Summary

Subnetwork	Coverage
PIK3CA and neighbors	64.8% (1286 / 1984 samples)
ARID1A, PBRM1, and neighbors	64.6% (1281 / 1984 samples)
Cohesin and neighbors	47.6% (945 / 1984 samples)
C3, THBS1, CFH, COL3A1, ITGAX, LAMA1	30.7% (609 / 1984 samples)
TG, LPA, ANKS1B, LRP2	28.2% (559 / 1984 samples)
AXIN2, RPI, APC, PTPN13	27.0% (535 / 1984 samples)
BRIP1, BAP1, BRCA1	24.3% (483 / 1984 samples)
PTPRS, CDH1, PTPRK, PPFIA2, PTPRM	24.3% (482 / 1984 samples)
MYC, DNMT3A, DNMT1	22.8% (453 / 1984 samples)
ANK1, LICAM, NCAN, TNC	21.9% (435 / 1984 samples)
CCNE1, NOTCH3, NOTCH4, FBXW7	20.5% (406 / 1984 samples)
SLIT3, ROBO2, ROBO1, SLIT2, SRGAP1	17.9% (355 / 1984 samples)
MCL1, BCL2L1, BCLAF1	16.8% (333 / 1984 samples)
NTRK1, NTRK3, RASGRF1	16.3% (324 / 1984 samples)
MYO7A, NFE2L2, KEAP1	16.1% (319 / 1984 samples)
MLLT4, EPHA7, NRXN3	15.2% (302 / 1984 samples)
COL4A1, COL4A5, COL4A6, FBLN2	11.8% (234 / 1984 samples)
OPRM1, GRM1, GPRASP1	10.8% (215 / 1984 samples)
CDH18, CDH12, CDH10, CDH9	10.6% (211 / 1984 samples)
FLNA, CALCR, GRM8, CASR	10.1% (201 / 1984 samples)

KIRC


OV

Mutations Types

■ SNV ■ AMP ■ DEL



SLIT/ROBO signaling

Coverage: 10.3% (203/1984 samples)



Mutations / Gene

- 605
- 576
- 547
- 519
- 490
- 461
- 432
- 403
- 375
- 346
- 317
- 288
- 259
- 230
- 202
- 173
- 144
- 115
- 86
- 58
- 29



GBM: 0.002

Mutations by Cancer


- AML (0.5%)
- Luminal A (6%)
- Luminal B (18.5%)
- Basal-like (17.2%)
- **HER2-enriched (26.2%) ($p = 0.002$)**
- COADREAD (13.5%)
- GBM (6.9%)
- KIRC (6.8%)
- OV (12.9%)
- UCEC (9.6%)
- LUSC (19.8%)

Mutations Types

■ SNV ■ AMP ■ DEL


MYC, DNMT3A, DNMT1

Coverage: 21.7% (430/1984 samples)



Mutations / Gene

605
576
547
519
490
461
432
403
375
346
317
288
259
230
202
173
144
115
86
58
29



Mutations by Cancer


- AML (26%)
- Luminal A (11.6%)
- Luminal B (26.1%)
- Basal-like (49.4%)
- HER2-enriched (36.1%)
- COADREAD (16.8%)
- GBM (2.7%)
- KIRC (4.5%)
- **OV (55%) ($p = 3.63 \times 10^{-45}$)**
- UCEC (11.4%)
- LUSC (18.6%)

Mutations Types

■ SNV ■ AMP ■ DEL




SLIT/ROBO signaling

Coverage: 10.3% (203/1984 samples)





Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

Nature (Nov. 15, 2012) ^a






Summary



Mutation & copy number



HotNet



Next Steps

- Additional QC on mutation data
 - Target gene selection on copy number aberrations
- Incorporate background mutation model
- Incorporate other data types: e.g. expression and/or methylation
- Dendrix: exclusivity

Acknowledgements

Fabio Vandin
Eli Upfal
Max Leiserson
Hsin-Ta Wu
Adrien Deschamps
Jason Shum



Tim Ley
Li Ding
Chris Miller
Elaine Mardis
Rick Wilson
and others...



HotNet and Dendrix Available

Web: <http://compbio.cs.brown.edu/software>